Cannabis Stocks Rally: CGC +19%, Curaleaf +26% on Schedule III Order

Cannabis stocks posted their biggest single-day rally in years on April 22, 2026, as word circulated that the Trump administration was preparing to sign a Schedule III order for state-licensed medical cannabis. The gains were broad, concentrated at the top of the industry, and timed to an event that actually delivered — the DOJ signed the order the following day, April 23. For publicly traded operators that have spent years trading on promise, the Schedule III catalyst finally arrived.

The session's headline numbers captured the scale of the repricing. Canopy Growth (CGC) gained 21.1%. Tilray (TLRY) finished up 14.2%. Curaleaf (CURLF) surged 26.3%. The AdvisorShares Pure US Cannabis ETF (MSOS) — the most widely held US cannabis ETF — closed up 19.4% on volume many multiples of its recent average. For a sector that entered 2026 well off its 2021 highs, the move represents the largest reset in the 280E era.

Why the Market Moved

The catalyst was specific: state-licensed medical cannabis moving from Schedule I to Schedule III of the Controlled Substances Act. That single change eliminates Section 280E of the Internal Revenue Code for qualifying sales — a provision that has barred cannabis operators from deducting ordinary business expenses and pushed effective federal tax rates above 75% for some companies.

Removing 280E on medical sales is an immediate improvement in margins, cash flow, and reported net income for every multi-state operator with a meaningful medical footprint. It also potentially unlocks retroactive tax relief — the DOJ order encourages the Treasury to consider refunds for prior tax years operated under state medical licenses. Publicly traded operators have disclosed 280E-related deferred tax balances in the hundreds of millions of dollars; retroactive relief, if granted, would materially change balance-sheet comparisons.

Equity investors also repriced the probability of broader rescheduling. The DOJ order directed the DEA to convene an expedited administrative hearing beginning June 29, 2026 to consider moving all cannabis — including adult-use — to Schedule III. A market that has priced full rescheduling as a long-tail possibility for years responded to the compressed timeline by compressing the discount.

Who Benefited Most

Curaleaf's 26.3% move topped the large US multi-state operators. The company has one of the larger medical-focused footprints among MSOs and the most direct exposure to the 280E reversal. Its 280E tax liability has been one of the largest reported in the industry, making it also one of the largest beneficiaries of any Treasury retroactive relief scenario.

Canopy Growth's 21.1% gain reflected a mix of factors — the Canadian licensed producer has long-dated ambitions in the US market and has structured its US exposure to activate on federal permissibility events. A Schedule III signal for US medical cannabis materially changes the calculus for Canopy's US entry plans.

Tilray's 14.2% move was the most modest among the majors but arrived on top of an already strong fiscal run. The company's diversified revenue base, including non-cannabis beverage assets, means pure-play 280E reversal moves less of its earnings line — though it still benefits.

The MSOS ETF's 19.4% gain captured the breadth of the rally. As the dominant retail-accessible vehicle for US cannabis exposure, MSOS registered inflows on the session and saw options volume surge as market participants hedged, initiated, and rolled positions around the catalyst.

What Changed on April 23

The rally began on pre-order speculation and was confirmed when Acting Attorney General Todd Blanche signed the Schedule III order on April 23. The order covers FDA-approved drug products containing marijuana and marijuana products regulated under a qualifying state medical marijuana license. Recreational cannabis — even when sold by the same public company through the same retail footprint — remains Schedule I until the DEA's June 29 hearing considers broader rescheduling.

For investors, this creates a two-track earnings picture for vertically integrated multi-state operators. Medical-licensed sales become immediately deductible under Schedule III; adult-use sales continue to carry the 280E burden until or unless the broader hearing extends relief. Operators with heavier medical mixes — Curaleaf, Trulieve, Cresco — see the largest immediate margin lift. Operators more weighted toward adult-use — Green Thumb, Verano, some state-specific plays — see a narrower near-term benefit but similar long-term upside if Schedule III is extended.

Volume, Options, and Retail Flows

Session volume on the major cannabis names ran multiples of recent averages. MSOS traded well above its year-to-date daily average, and the cannabis names accounted for an outsized share of the day's top-percentage gainers on both US and Canadian exchanges.

Options markets showed characteristic patterns of a confirmed catalyst. Short-dated calls expiring in May and June traded at volatility premiums well above historical levels, reflecting both the June 29 DEA hearing and the possibility of further executive or legislative action. Put skew compressed as tail risk on the downside diminished for the largest operators. The MSOS options surface shifted aggressively, with retail-oriented upside calls seeing significant new open interest.

Flows into MSOS tell the retail story. The ETF has served as the primary retail access point to US cannabis since its 2020 launch, and April 22 saw one of its largest inflow sessions on record.

What Could Undo the Rally

Two risks sit immediately ahead. Smart Approaches to Marijuana, a legalization-opposition advocacy group, announced it would pursue legal action to challenge the DOJ order on procedural grounds. The most plausible legal arguments center on whether the DOJ could act via order rather than the standard APA rulemaking path. An injunction or adverse ruling could freeze the order pending further proceedings, which would re-introduce uncertainty into every operator's 2026 tax planning.

The second risk is the DEA hearing itself. A narrower-than-expected outcome — Schedule III for medical with a longer phased path for adult-use, or additional conditions attached to scheduling — would leave the large recreational revenue lines under 280E for longer than the market is currently pricing. Any indication that the hearing is being delayed or materially scoped would likely reprice the rally.

A third, slower risk is enforcement. Schedule III substances are still controlled. Pharmaceutical-grade record-keeping, secure storage, and federal reporting requirements apply in ways that state medical programs have not had to navigate before. Compliance capital expenditures will rise, partly offsetting the 280E margin benefit for operators that need to upgrade systems.

Fundamentals vs. the Trade

For investors parsing whether April 22 was a one-day catalyst trade or the start of a longer re-rating, the fundamentals matter. The 280E reversal is worth material recurring dollars to operators — not a one-time gain. The retroactive relief, if granted, is one-time but potentially substantial. Research access eases slowly but improves the long-run product and science runway.

At the same time, the cannabis industry has not solved its other structural issues. Price compression in mature state markets continues. Capital costs remain elevated relative to traditional CPG peers. Banking access has improved but remains constrained. And the adult-use half of the US market still sits under 280E until and unless the DEA hearing delivers a broader change.

Key Takeaways

• Cannabis stocks posted their largest single-day rally in years on April 22, 2026 ahead of the DOJ Schedule III order.
• CGC gained 21.1%, TLRY 14.2%, CURLF 26.3%, and the MSOS ETF 19.4%.
• The rally reflects immediate 280E reversal for state-licensed medical cannabis and compressed timelines for broader rescheduling.
• Recreational cannabis revenue remains under 280E until the June 29 DEA hearing considers extending Schedule III.
• Legal challenges from SAM and the scope of the DEA proceeding are the near-term risks to monitor.

Explore cannabis news, find dispensaries, and join the community at Budpedia.